SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Sexual HealthFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Gonadorelin

Also known as Gonadorelin (GnRH), gnrh, lhrh, gonadorelin acetate · Wikipedia

Gonadorelin is synthetic native gonadotropin-releasing hormone (GnRH/LHRH), a decapeptide identical to the endogenous hypothalamic releasing factor. Pulsatile administration stimulates pituitary LH and FSH secretion, supporting fertility and HPG-axis function in both sexes. Historically FDA-approved as Factrel (diagnostic pituitary challenge) and Lutrepulse (ovulation induction via pulsatile pump); both products have been withdrawn from the US market. Compounded gonadorelin is now widely used off-label by TRT clinics as an HCG alternative and post-cycle therapy adjunct. Veterinary formulations remain commercially available for research applications.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Gonadorelin is synthetic native GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), an unmodified decapeptide identical to endogenous hypothalamic gonadotropin-releasing hormone. It binds GnRHR on anterior pituitary gonadotrophs to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which then drive testicular Leydig-cell testosterone production and ovarian follicular development.

Gonadorelin is synthetic native GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), an unmodified decapeptide identical to endogenous hypothalamic gonadotropin-releasing hormone. It binds GnRHR on anterior pituitary gonadotrophs to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which then drive testicular Leydig-cell testosterone production and ovarian follicular development. Critically, pulsatile administration (every 60-120 minutes) drives physiologic LH/FSH release and gonadal steroidogenesis, whereas continuous administration paradoxically desensitizes and downregulates GnRHR — the basis for GnRH-agonist suppression in prostate cancer and endometriosis (Filicori et al., PMID 2122733).

Pharmacokinetic properties

Half-life

~2-10 minutes plasma (very short - reason pulsatile dosing must be frequent)

Routes

intravenous · subcutaneous · intramuscular

Bioavailability

SC and IV both work. Oral bioavailability negligible. Historically delivered via Lutrepulse OmniPod pump for pulsatile fertility induction.

Amino-acid sequence

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Use & research dosing

Fertility SupportHPG Axis Stimulation

Historical FDA-approved Factrel diagnostic: 100 mcg SC or IV single dose for pituitary function testing. Lutrepulse pulsatile pump: 5-20 mcg IV every 90 minutes for ovulation induction over 14-21 days per cycle. Off-label TRT-adjunct protocols commonly report 100-300 mcg SC every 1-3 days to preserve testicular function during exogenous testosterone. The very short ~2-10 minute plasma half-life limits effectiveness of infrequent bolus dosing. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Current state: Native gonadorelin has solid historical FDA approval and decades of fertility-medicine evidence, but both branded products are off the US market. Almost all current US human use is compounded, off-label, and centered on TRT/PCT settings — a context with little controlled trial support. The pharmacology argues that infrequent SC bolus dosing cannot mimic physiologic pulsatile release, tempering claims of testicular preservation versus HCG.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Hypersensitivity to gonadorelin or GnRH analogs
  • Hormone-sensitive malignancy (prostate, breast) — paradoxical flare risk with bolus dosing
  • Pregnancy — not indicated
  • Bolus dosing produces only brief LH/FSH pulse; not equivalent to HCG for sustained Leydig support
  • Anaphylaxis and hypersensitivity reactions reported, rare
  • Pituitary apoplexy reported, very rare
  • Compounded product purity and dose accuracy variable
  • Off-label TRT-adjunct use lacks long-term efficacy data for testicular preservation

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/2122733/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/14973957/

Facts verified

2026-05-25

Confidence

medium

What this means

  • FDA-approved products (Factrel, Lutrepulse) withdrawn from US market
  • Current human use is compounded and off-label
  • TRT-adjunct dosing protocols lack controlled-trial support
  • Bolus SC dosing cannot reproduce physiologic pulsatile release

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.